TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05714995

Intervention type: OTHER
Intervention: hypnosis
Description: The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance

Intervention type: OTHER
Intervention: Hypnosis with aromatherapy
Description: for patients in the hypnosis with aromatherapy group, before starting the hypnosis session, they will first choose an essential oil among the 5 proposed.~They will pour a drop on their wrist then they will rub it and inhale deeply.~The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance
Study: NCT06447064

Intervention type: OTHER
Intervention: Cases & Controls
Description: Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will need to provide a photo ID and utility bill for ID verification. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.

Intervention type: OTHER
Intervention: Cases & Controls
Description: Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will need to provide a photo ID and utility bill for ID verification. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.
Study: NCT05958329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback
Description: 5 minute daily sessions of HRV biofeedback
Study: NCT05315284

Intervention type: PROCEDURE
Group type: OTHER
Intervention: the Use of Titanium Elastic Nail in The Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
Description: Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
Study: NCT04773639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modal Palliative Care Intervention
Description: An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care Control Condition
Description: The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
Study: NCT06026319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD79b-19 CAR T cells
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion
Study: NCT05781893

Intervention type: OTHER
Intervention: Digital intervention (DiLCoS)
Description: The DiLCoS substudy comprises a digital intervention. A smartphone app is used to provide the patient with a 12-week exercise program, including physical elements (in the form of breathing exercises, relief positions and relaxation techniques), psychoeducational elements (e.g., information about fatigue, neurocognitive symptoms, media consumption, healthy diet), self-monitoring elements (activity planning, energy management), and psychological elements (e.g., guided exercises to improve acceptance of current situation, cognitive distancing from negative thoughts, imagination techniques for pain management). It holds promise for significantly improving the management and quality of life of individuals living with PCC.

Intervention type: OTHER
Intervention: Data collection
Description: Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.

Intervention type: OTHER
Intervention: Data collection
Description: Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.
Study: NCT05176782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTK cardioplegia
Description: will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold Cadioplegia
Description: as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
Study: NCT06317519

Intervention type: PROCEDURE
Intervention: Physical Rehabilitation
Description: 5 sessions of physical rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.

Intervention type: PROCEDURE
Intervention: Physical Rehabilitation
Description: 5 sessions of physical rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.

Intervention type: DEVICE
Intervention: Gait Real-time Analysis Interactive Lab
Description: 5 sessions of GRAIL assisted rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
Study: NCT04658303

Intervention type: DRUG
Intervention: Pimonidazole
Description: Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
Study: NCT05627401

Intervention type: PROCEDURE
Intervention: Modified multiple orbital wall decompression
Description: Thyroid dysfunction of all patients is stabilized by ATDs until treatment of TAO is completed. All patients with sight-threatening GO were admitted for emergency steroid pulse therapy. And additional drugs for protecting gastrointestinal mucous membrane, potassium and calcium supplements, and sedatives were used. All emergency cases, whose signs of visual impairment clinically attributable to GO existed despite first-line steroid treatment, were referred and discussed at the surgical board of our interdisciplinary center for prompt surgical orbital decompression. Urgent orbital decompression was performed when response is absent or poor within 1-2 weeks.
Study: NCT04703634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block (ESP)
Description: Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae block (ESP)
Description: Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
Study: NCT04930107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 150 mg
Description: Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Females presenting with a suspected first-time yeast infection will be treated with fluconazole 150 mg orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boric Acid Supp,Vag
Description: Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Women that have had a prior documented VVC infection that has recurred on fluconazole will be treated with boric acid, 600 mg intravaginally at bedtime for 7 days.
Study: NCT06006494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic
Description: We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week.
Study: NCT05664139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
Description: Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death.
Study: NCT02365974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Stimulation
Description: TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No Transcutaneous Electrical Stimulation
Description: The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
Study: NCT06109506

Intervention type: PROCEDURE
Intervention: Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess
Description: Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses \> 4-5 cm, percutaneous image-guided drainage.

Intervention type: PROCEDURE
Intervention: Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess
Description: Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses \> 4-5 cm, percutaneous image-guided drainage.
Study: NCT04748419

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: consolidative hypofractionated radiation therapy (hfRT)
Description: Consolidative hfRT will start from 6.5Gy x 2 fractions and dose escalate to 10Gy x 2 fractions in a 3+3 design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/ML
Description: Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
Study: NCT05721443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib+cetuximab
Description: The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met.
Study: NCT05878782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCRO+Occupational therapy
Description: Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCRO without intervention
Description: Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
Study: NCT06081374

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: simulation implication
Description: Breastfeeding education is planned by dressing pregnant women with simulation models.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simulation implication
Description: Breastfeeding education is planned by dressing pregnant women with simulation models.
Study: NCT04944030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasis biopsy
Description: Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasis biopsy
Description: Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasis biopsy
Description: Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
Study: NCT06187350

Intervention type: DEVICE
Intervention: AI cancer detection system
Description: The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score \> 7 will be double-reviewed as normal.
Study: NCT04186676

Intervention type: OTHER
Intervention: MINOCA registry
Description: Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA Phenotypes
Description: 1. Complete normal coronary arteries~2. Diffuse non-obstructive coronary artery disease~3. Non-obstructive high-risk plaques~4. Myocardial bridges
Study: NCT04978610

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Acceptance Commitment Therapy
Description: For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Acceptance Commitment Therapy
Description: For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes.
Study: NCT06006494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic
Description: We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic
Description: We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistant
Description: Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
Study: NCT06358846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care behavior to promote foot care through educational guidance among individual with diabetes
Description: Apart from physician consultation, individuals will received structured training of how to care their foot to avoid ulcer and inflammation.
Study: NCT05146739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV and IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Give PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Intrathecal Chemotherapy
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study: NCT05127850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation audio recording app
Description: Smartphone or tablet mobile application which allows for voice recording
Study: NCT03928808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
Study: NCT05313022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZR-202-CoV
Description: Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study: NCT04504825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAEL-101
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% Normal Saline will be used as the placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.
Study: NCT06223750

Intervention type: OTHER
Group type: OTHER
Intervention: population-based screening for chronic kidney disease
Description: Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments

Intervention type: OTHER
Group type: OTHER
Intervention: population-based screening for chronic kidney disease
Description: Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
Study: NCT06644469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynatronics VF5 Model vibration platform
Description: The Dynatronics VF5 Model vibration platform is a specialized therapeutic device designed for rehabilitation and wellness applications. Utilizing advanced vibration technology, it provides whole-body vibration therapy that can enhance muscle strength, improve flexibility, and promote overall physical well-being. The platform features adjustable frequency and amplitude settings, allowing customization based on individual needs. Its user-friendly interface and robust, durable design make it suitable for both clinical and mobile therapy settings. Additionally, the compact and portable nature of the VF5 facilitates easy storage and transport, while safety features such as non-slip surfaces ensure user protection.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dynatronics VF5 Model vibration platform
Description: Placebo intensity with vertical vibration of 0.2 mm